Summary of Study
The study “Systematic Review and Dosage Analysis: Hyperbaric Oxygen Therapy for Mild Traumatic Brain Injury and Persistent Postconcussion Syndrome” evaluates the effectiveness of hyperbaric oxygen therapy (HBOT) for individuals suffering from mild traumatic brain injury (mTBI) and Persistent Postconcussion Syndrome (PPCS). The research aims to determine the optimal HBOT dosage and its impact on cognitive function and neurological symptoms. The study addresses whether hyperbaric therapy at specific pressures and oxygen concentrations can significantly improve cognitive deficits, emotional well-being, and overall quality of life for individuals with PPCS.
Methodology
The researchers conducted a systematic review using databases such as PubMed, CINAHL, and the Cochrane Systematic Review Database. Studies were included if they examined adults with PPCS lasting at least three months and if HBOT was administered as a treatment. The selected studies were categorized based on hyperbaric treatment pressure levels, oxygen dosages, and frequency of sessions. A total of 11 studies, including randomized controlled trials (RCTs), case-controlled studies, and case reports, were analyzed. The risk of bias was assessed using the PEDro Scale, ensuring the validity and reliability of the results.
Results
The review found that HBOT at 1.5 atmospheres absolute (ATA) oxygen significantly improved cognitive function, reduced symptoms, and enhanced overall neurological recovery. Patients who received hyperbaric oxygen therapy at this dosage reported better concentration, memory, and reduced headaches. Studies using lower pressures (1.2 ATA air) or higher pressures (2.4 ATA oxygen) showed inconsistent results, suggesting that the effectiveness of HBOT is dose-dependent. Additionally, individuals with comorbid post-traumatic stress disorder (PTSD) responded more positively to the therapy. The findings highlight that hyperbaric chamber treatments at the right pressure can play a critical role in post-concussion recovery.
Conclusion
The study concludes that hyperbaric oxygen therapy at 1.5 ATA is an effective intervention for Persistent Postconcussion Syndrome, improving cognitive function and reducing long-term symptoms. However, the study emphasizes the need for larger, well-controlled clinical trials to confirm these findings and refine treatment protocols. HBOT offers a promising avenue for individuals suffering from mTBI-related cognitive impairments, but additional research is necessary to establish standardized guidelines for its use in medical practice.
Source: Systematic Review and Dosage Analysis: Hyperbaric Oxygen Therapy for Mild Traumatic Brain Injury and Persistent Postconcussion Syndrome | Paul G. Harch | Front. Neurol. , 16 March 2022, Sec. Neurotrauma | DOI: 10.3389/fneur.2022.815056
